---
title: "\"Performance\" and Yu's annual net profit of 55.25 million RMB increased by 95.2% with no dividend distribution"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277488826.md"
description: "HeYu-B announced its 2025 annual performance, with revenue of 612 million RMB, an increase of 21.5% year-on-year. It recorded a net profit of 55.25 million RMB, a growth of 95.2%, with earnings per share of 0.09 RMB. No final dividend is declared"
datetime: "2026-03-02T15:12:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277488826.md)
  - [en](https://longbridge.com/en/news/277488826.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277488826.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277488826.md) | [繁體中文](https://longbridge.com/zh-HK/news/277488826.md)


# "Performance" and Yu's annual net profit of 55.25 million RMB increased by 95.2% with no dividend distribution

HeYu-B (02256.HK) announced its 2025 annual results, with revenue of RMB 612 million, an increase of 21.5% year-on-year. It recorded a net profit of RMB 55.25 million, a growth of 95.2%, with earnings per share of 9 cents. No final dividend is declared

### Related Stocks

- [AKESO (09926.HK)](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Guotai Haitong Remains a Buy on Zai Lab Ltd (1ZLB)](https://longbridge.com/en/news/277338249.md)
- [Okura Holdings Delivers Modest Profit Growth as Revenue Rises but Costs Creep Up](https://longbridge.com/en/news/277240582.md)
- [Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals](https://longbridge.com/en/news/277340041.md)
- [Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial](https://longbridge.com/en/news/277696391.md)
- [Tesla Makes Major Change to FSD Transfer Policy and March 31 Deadline](https://longbridge.com/en/news/277314843.md)